A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)

2024-511116-25-00 Protocol ARC-12 Human pharmacology (Phase I) - First administration to humans Ended

Start 13 Dec 2022 · End 26 Aug 2025 · Status Ended · 2 EU/EEA countries · 7 sites · Protocol ARC-12

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 94
Countries 2
Sites 7

Multiple Myeloma

Key facts

Sponsor
Arcus Biosciences Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Dec 2022 → 26 Aug 2025
Decision date (initial)
2024-05-31
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-511116-25-00
EudraCT number
2021-005589-16
ClinicalTrials.gov
NCT04772989

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Multiple Myeloma

VersionLevelCodeTermSystem organ class
21.0 LLT 10048683 Advanced cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Arcus Biosciences Inc.

Sponsor organisation
Arcus Biosciences Inc.
Address
3928 Point Eden Way
City
Hayward
Postcode
94545-3719
Country
United States

Scientific contact point

Organisation
Arcus Biosciences Inc.
Contact name
Medical Director

Public contact point

Organisation
Arcus Biosciences Inc.
Contact name
Medical Director

Locations

2 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Poland Ended 7 2
Spain Ended 11 5
Rest of world
United States
76

Investigational sites

Poland

2 sites · Ended
Med Polonia Sp. z o.o.
N/A, Obornicka 262, 60-693, Poznan
Hlk Sp. z o.o.
N/A, Ul. Witolda Chodzki 17/6, 20-093, Lublin

Spain

5 sites · Ended
Hospital Universitario 12 De Octubre
Servicio de Oncologia Medica, Bloque D, Avenida De Cordoba Sn, Madrid
Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron
Materno Infantil, Passeig De La Vall D'hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
Start Unit, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Clinica Universidad De Navarra
Departamento De Oncología, Avenue Pio XII 36, 31008, Pamplona
Clinica Universidad De Navarra
N/A, Calle Marquesado De Santa Marta 1, 28027, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Poland 2022-12-13 2023-03-16 2023-06-01
Spain 2023-01-04 2023-01-05 2023-04-13

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-04-02 Spain Acceptable
2024-05-10
2024-05-10
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-05 Spain Acceptable
2024-11-04
2024-11-06
3 SUBSTANTIAL MODIFICATION SM-2 2025-01-16 Spain Acceptable
2025-02-24
2025-02-24